New pill may stop vomiting from weight-loss drugs

NCT ID NCT06804603

Completed Symptom relief Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether tradipitant, an oral capsule, can reduce nausea and vomiting in healthy overweight or obese volunteers who also received a GLP-1 receptor agonist (a class of weight-loss drugs). 124 participants were randomly assigned to tradipitant or a placebo. The main goal was to see if fewer people in the tradipitant group had vomiting episodes each week, tracked using a daily symptom diary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tradipitant
What this could lead to: If it works, tradipitant could help people taking GLP-1 drugs for weight loss or diabetes by reducing the nausea and vomiting that often cause people to stop treatment.
What could go wrong: This is a small, early-phase study in healthy volunteers, not patients. The results may not apply to real-world use, and tradipitant might not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Nausea Obesity obesity disorder Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Vanda Investigational Site

Los Angeles, California, 90025, United States
Vanda Investigational Site

Rochester, Minnesota, 55905, United States
Vanda Investigational Site

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.